Skip to main content

Ariadna Laguna Tuset

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Ariadna Laguna Tuset

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am a neuroscientist with extensive experience in the molecular mechanisms underlying both neurodevelopmental and neurodegenerative diseases of the nervous system. My current research is aimed at identifying new therapeutic targets and biomarkers to improve the diagnosis and treatment of Parkinson's disease.

I received my Biology degree, Health and Life Sciences specialization, in 2003 at the Universitat Pompeu Fabra (Barcelona, Spain). I got my Ph.D. in 2008 in the laboratory of Dr. Mariona Arbonés at the Center for Genomic Regulation (CRG, Barcelona, Spain). My Ph.D. was devoted to study the molecular basis of Down Syndrome neurological alterations. In 2009, I joined the group of Professor Thomas Perlmann at the Ludwig Institute for Cancer Research – Karolinska Institutet (Stockholm, Sweden) as a post-doctoral Marie Curie researcher to work on the transcriptional regulation of dopamine neurons during development and in pathological conditions such as Parkinson’s disease.

In 2014, I moved back to Barcelona and joined the Neurodegenerative Diseases Research Group at the Vall d’Hebron Research Institute (VHIR) as a Beatriu de Pinós post-doctoral researcher funded by AGAUR-FP7 Marie Curie Actions. Afterwards, I received a Young Investigator contract from the Spanish government (Ministry of Economy and Competitiveness (MINECO)) and a Junior Leader fellowship from the La Caixa Foundation to establish my own research lines within the group. In addition, I am an associate researcher at the Neuroscience Institute of the Autonomous University of Barcelona (UAB) and Scientific Ambassador of the World Parkinson Coalition.

The research from my team is devoted to elucidate the molecular mechanisms of inter-organ communication in Parkinson’s disease and how this contributes to the pathophysiology and symptoms of this neurodegenerative disorder. Our research contributes to: (i) identify biomarkers for early detection, disease progression or response to treatment, (ii) identify new molecular targets and develop novel therapeutic strategies with disease-modifying potential, (iii) unravel molecular pathways common to other neurodegenerative or metabolic diseases. Researcher ID: F-9561-2016; Orcid: 0000-0002-9732-6677.

Research lines

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Miquel Vila Bover, Ariadna Laguna Tuset

Projects

PAIR: Parkinson’s Intergenerational Care

IP: Ariadna Laguna Tuset
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 20000
Reference: EC/IMPETUS/2024/LAGUNA
Duration: 07/06/2024 - 17/01/2025

diVHulga. Programa anual de actividades UCC+I del Campus Vall d’Hebron (VH)

IP: Immaculada Hernández Rodríguez
Collaborators: Josep Quer Sivila, Sara Ruiz Gallardo, Mayte Serrat Lopez, Julia Basallote Garciade Quiros, Beatriz Blasco Perez, Ariadna Laguna Tuset, Diana Fernandes de Rafael
Funding agency: Fundación Española Ciencia y Tecnología (FECYT)
Funding: 30000
Reference: FCT-23-19812
Duration: 01/07/2024 - 30/06/2025

Tejiendo Ciencia

IP: Ariadna Laguna Tuset
Collaborators: Anna Santamaria Margalef, Maria Mar Hernandez Guillamon, Sara Mas Assens
Funding agency: Fundación Española Ciencia y Tecnología (FECYT)
Funding: 15000
Reference: FCT-23-19804
Duration: 01/09/2024 - 31/08/2025

The brain-body axis in Parkinson's disease for biomarker and therapeutic development (BRAIN-BODY-PD)

IP: Ariadna Laguna Tuset
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 199998.14
Reference: CNS2023-145555
Duration: 01/04/2024 - 31/03/2026

Ministerio de Ciencia

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Maria José Evangelio Sequi

Maria José Evangelio Sequi

General Surgery
Read more
Esther Gil Barrionuevo

Esther Gil Barrionuevo

General Surgery
Read more
Mireia Verdaguer Tremolosa

Mireia Verdaguer Tremolosa

Research technician
General Surgery
Read more
Pablo Vilalta Gras

Pablo Vilalta Gras

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.